Effect of Exenatide on serum fibroblast growth factor-21 level in patients with type 2 diabetes

杨琨,王海宁,洪天配,魏蕊,杨进
DOI: https://doi.org/10.3969/j.issn.1006-6187.2017.04.010
2017-01-01
Abstract:Objective Fibroblast growth factor-21 (FGF-21) plays an important role in regulating the metabolism of glucose and lipid.This study aims to investigate the effect of Exenatide on serum FGF-21 level in patients with type 2 diabetes (T2DM).Methods 240 T2DM patients inadequately controlled by monotherapy or combination therapy with Metformin and insulin secretagogues were recruited in this exploratory multicenter clinical trial.All the patients received an add-on therapy with Exenatide by subcutaneous injection for 16 weeks.Serum FGF-21 level and other metabolic parameters were measured before and after Exenatide treatment.Results Finally,203 subjects completed the treatment and follow-up,with mean age (49.5±9.9) years and median diabetes duration 4.75 (2.33,8.25) years.The levels of HbA1c and body weight significantly decreased after treatment [(8.21±0.90)% vs (7.02±1.05)% and (79.93±15.00) vs (77.94±14.76) kg,respectively,P<0.001].Serum FGF-21 level increased after treatment [151.27 (108.06,224.14) vs 143.97 (99.90,213.90) pg/ml,P<0.05].Conclusion In poorly controlled T2DM patients with Metformin and insulin secretagogues monotherapy or combination therapy,the addition of Exenatide treatement can not only effectively lower blood glucose and body weight,but also increase serum FGF-21 level.
What problem does this paper attempt to address?